# Wyze

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/wyze

- Industry: Biotechnology
- Headquarters: Zhongshan, China
- Total disclosed funding: $30M
- Latest round: Series A (Aug 17, 2022)
- Investors on record: 6

## About

Established in 2012 and based in Zhongshan, China, Wyze is a biomedical company that focuses on the development DNT immune cell drugs. In 2021, the company changed its name from Zhejiang Ruishun Biotechnology Co., Ltd. to Guangdong Ruishun Biotechnology Co., Ltd. The company's chairman and chief scientific officer is Liming Yang.

The company provides DNT immune cell drugs for patients with malignant tumors and autoimmune diseases. The product of company includes NALE antibodies, flow cytometry auxiliary reagents and CART (chimeric antigen receptor t cell therapy) cells. The business of company includes the development, production and sales of stem cells, immunobiology scientific research and diagnostic reagents. The DNT cell platform of the company adopts CART technology, gene editing technology and induced pluripotent stem cells (iPSC) technology.

## Funding rounds

- Series A, Aug 17, 2022, $8.7M — Yuecai Zhongyin Private Equity, Baidu Ventures
- Series A, Oct 22, 2021, $21M — TTGG Ventures, Fuho Capital, ZJKF Capital Management, Huaxia Hengtian Asset Management

## Investors

- TTGG Ventures (https://capitalatlas.ai/funds/ttgg-ventures) — Series A
- Fuho Capital (https://capitalatlas.ai/funds/fuho-capital) — Series A
- ZJKF Capital Management (https://capitalatlas.ai/funds/zjkf-capital-management) — Series A
- Huaxia Hengtian Asset Management (https://capitalatlas.ai/funds/huaxia-hengtian-asset-management) — Series A
- Yuecai Zhongyin Private Equity (https://capitalatlas.ai/funds/yuecai-zhongyin-private-equity) — Series A
- Baidu Ventures (https://capitalatlas.ai/funds/baidu-ventures) — Series A